Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?

Future Oncol. 2019 Mar;15(9):925-927. doi: 10.2217/fon-2018-0503. Epub 2019 Mar 11.
No abstract available

Keywords: immunotherapy; renal cell carcinoma; tyrosine kinase inhibitors.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / mortality
  • Carcinoma, Renal Cell / pathology*
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / mortality
  • Kidney Neoplasms / pathology*
  • Protein Kinase Inhibitors / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors